{"id":5542,"date":"2022-06-17T15:53:11","date_gmt":"2022-06-17T14:53:11","guid":{"rendered":"https:\/\/touchimmunology.com\/?post_type=media_gallery&p=5542"},"modified":"2022-06-17T15:53:11","modified_gmt":"2022-06-17T14:53:11","slug":"5542","status":"publish","type":"media_gallery","link":"https:\/\/touchimmunology.com\/digestive-disorders\/conference-hub\/5542\/","title":{"rendered":"Marla C. Dubinsky, DDW 2022: LUCENT-2 Study – Mirikizumab Maintenance Therapy in Moderate-to-Severe Ulcerative Colitis (Part 1)"},"content":{"rendered":"

The LUCENT-2 study (ClinicalTrials.gov Identifier: NCT03524092<\/a>) is a maintenance study of mirikizumab in patients with moderate-to-severe ulcerative colitis (UC). <\/span>We were delighted to speak to Prof. Marla C. Dubinsky<\/strong> (Icahn School of Medicine, Mount Sinai, New York, NY, USA) around the rationale for the use of mirikizumab as a treatment for UC and the exciting clinical endpoints of this study.<\/span><\/p>\n

The abstract ‘EFFICACY AND SAFETY OF MIRIKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-2 STUDY.<\/em>‘ was presented at Digestive Disease Week 2022<\/a>, May 21-24, 2022.<\/span><\/p>\n

Questions<\/b><\/p>\n

    \n
  1. What is the rationale for the use of mirikizumab in the treatment of patients with moderate to severe ulcerative colitis? (0:21)<\/span><\/li>\n
  2. Could you tell us a little about the LUCENT clinical trial programme? (0:44)<\/span><\/li>\n
  3. What were the clinical endpoints and baseline characteristics of the LUCENT-2 study? (1:40)<\/span><\/li>\n<\/ol>\n

    Disclosures:<\/b> Marla C. Dubinsky discloses consulting and serving on advisory boards for Lilly.<\/span><\/p>\n

    Support:<\/b> Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.<\/span><\/p>\n

    Filmed in coverage of DDW 2022.<\/i><\/b><\/p>\n","protected":false},"excerpt":{"rendered":"

    The LUCENT-2 study (ClinicalTrials.gov Identifier: NCT03524092) is a maintenance study of mirikizumab in patients with moderate-to-severe ulcerative colitis (UC). We were delighted to speak to Prof. Marla C. Dubinsky (Icahn School of Medicine, Mount Sinai, New York, NY, USA) around the rationale for the use of mirikizumab as a treatment for UC and the exciting […]<\/p>\n","protected":false},"featured_media":5543,"template":"","class_list":["post-5542","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-digestive-disorders","video_categories-ddw"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery\/5542","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":7,"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery\/5542\/revisions"}],"predecessor-version":[{"id":5614,"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery\/5542\/revisions\/5614"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media\/5543"}],"wp:attachment":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media?parent=5542"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}